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Abstract
Background Thyroid nodules are a common clinical problem, and differentiated thyroid cancer is becoming increasingly 
prevalent.
Methods Six scientific Italian societies entitled to cure thyroid cancer patients (the Italian Thyroid Association, the Medical 
Endocrinology Association, the Italian Society of Endocrinology, the Italian Association of Nuclear Medicine and Molecular 
Imaging, the Italian Society of Unified Endocrine Surgery and the Italian Society of Anatomic Pathology and Diagnostic 
Cytology) felt the need to develop a consensus report based on significant scientific advances occurred in the field.
Objective The document includes recommendations regarding initial evaluation of thyroid nodules, clinical and ultrasound 
criteria for fine-needle aspiration biopsy, initial management of thyroid cancer including staging and risk assessment, 
surgical management, radioiodine remnant ablation, and levothyroxine therapy, short-term and long-term follow-up strate-
gies, and management of recurrent and metastatic disease. The objective of this consensus is to inform clinicians, patients, 
researchers, and health policy makers about the best strategies (and their limitations) relating to the diagnosis and treatment 
of differentiated thyroid cancer.
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Abbreviations
PTMC  Papillary thyroid microcarcinoma
DTC  Differentiated thyroid cancer
Tg  Thyroglobulin
TgAb  Anti-thyroglobulin antibodies
rhTSH  Recombinant human TSH
WBS  Whole-body scan
RAI  Radioactive iodine
US  Ultrasound
FNA(C)  Fine-needle aspiration (cytology)
CCND  Central compartment neck dissection
LID  Low-iodine diet
MTA  Maximum tolerated activity (of radioiodine)
CN0  No clinical evidence of lymph nodes
Introduction
Although rare among human malignancies (< 1%), thy-
roid cancer of the follicular epithelium is the most frequent 
endocrine cancer, accounting for about 5% of thyroid nod-
ules. The latter are very frequent in the general population, 
and according to the method of detection and the subject’s Joint statements of six Italian societies: The Italian Thyroid 
Association (AIT), the Medical Endocrinology Association 
(AME), the Italian Society of Endocrinology (SIE), the Italian 
Association of Nuclear Medicine and Molecular Imaging (AIMN), 
the Italian Society of Unified Endocrine Surgery (SIUEC) and the 
Italian Society of Anatomic Pathology and Diagnostic Cytology 
(SIAPEC).
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age, their prevalence may approach 20–50% of the general 
population, thus representing a daily issue in endocrine clin-
ics. In recent decades, differentiated thyroid cancer (DTC), 
mainly papillary, has emerged as the most rapidly increasing 
human cancer worldwide. It is estimated that by the year 
2020, thyroid cancer will be the second most frequent cancer 
in women. The increase is believed to be mainly due to a 
screening effect after the introduction of neck ultrasonogra-
phy in daily practice performed for thyroid diseases but also 
for other unrelated conditions. Indeed, the large majority of 
thyroid cancers detected nowadays is constituted by the dis-
covery of non-palpable small tumors escaping recognition 
in the previous years. On the other hand, the rate of cancer-
related mortality does not seem to be at increase, although 
this aspect is still controversial. Based on this consideration, 
it is time to tailor diagnostic and therapeutic strategies for 
thyroid nodules and cancer according to the individual risk 
of recurrence or death. Management of the disease requires 
a multidisciplinary approach, including endocrinology, 
nuclear medicine, oncology, endocrine surgery, pathology, 
and even general practice operating in different settings not 
always equipped with the appropriate services (such as spe-
cialized centers, general hospitals, and peripheral centers). 
Diagnostic and treatment tools have significantly improved 
in recent years, thus allowing for less invasive and more 
comfortable procedures for the patients. Altogether, these 
considerations dictate the need for applying the more effec-
tive, less invasive, and less expensive procedures able to 
guarantee the best management and the best quality of life 
for a disease that albeit having an intrinsic low mortality 
requires life-long follow-up.
Several countries have developed their own guidelines 
or consensus reports, based on consolidated experience and 
cultural attitude of the country. Nevertheless, they differ in 
several, sometime important aspects. Following the spirit 
of a concrete cultural and scientific integration among dif-
ferent actors, the present document has been implemented 
and endorsed by six scientific societies entitled to cure thy-
roid cancer patients: the Italian Thyroid Association (AIT), 
the Medical Endocrinology Association (AME), the Ital-
ian Society of Endocrinology (SIE), the Italian Association 
of Nuclear Medicine and Molecular Imaging (AIMN), the 
Italian Society of Unified Endocrine Surgery (SIUEC) and 
the Italian Society of Anatomic Pathology and Diagnostic 
Cytology (SIAPEC).
The text is not intended to represent classical guidelines, 
but rather a collection of practical statements on selected 
relevant issues in the management of thyroid nodules and 
cancer, based on an adaptation of current guidelines (mainly 
the American Thyroid Association Guidelines) [1] according 
to the Italian situation and the expert opinion of the multi-
disciplinary panel.
Actions
For the implementation of the consensus, each of the six 
Societies selected its own experts for a total of 21 experts, 
including one coordinator. They met in ad hoc meeting that 
took place in Pisa on May 2016, where the relevant diagnos-
tic and therapeutic issues to be covered were identified. Each 
item was attributed to two members of the panel, who wrote 
the first draft of the statement, and then discussed in periodi-
cal plenary teleconferences until an agreement was reached. 
At this point, the panel met again in a meeting for final con-
sensus which took place in the Pontificia Accademia delle 
Scienze of the Vatican state, 15–16 September 2017. Experts 
were advised to base their statements on clinical and scien-
tific evidence whenever available in the current literature and 
on their own personal experience.
List of items
Item 1  Selection of thyroid nodules to be submitted to 
cytological evaluation.
Item 2  Based on cytology result, when thyroid surgery is 
indicated?
Item 3  What is the role of pre-operative staging with 
diagnostic imaging and laboratory tests?
Item 4  When surgery is indicated which strategy 
should be performed: total thyroidectomy or 
lobo-isthmectomy?
Item 5  No intervention for papil lary thyroid 
microcarcinoma.
Item 6  Indication for completion thyroidectomy after 
lobectomy.
Item 7  The role of central and lateral compartment neck 
dissection in the management of differentiated 
thyroid carcinoma (DTC).
Item 8  The need for a complete histological and cytologi-
cal report.
Item 9  Post-surgical thyroid ablation with radioiodine: 
routine or selective indication.
Item 10  Preparation for thyroid ablation and selection of 
the most appropriate activity.
Item 11  Informing the patient treated with radioactive 
iodine on safety measures.
Item 12  Follow-up after initial treatment (surgery and radi-
oiodine): when and how.
Item 13  Risk stratification incorporating the response to 
initial treatment.
Item 14  Follow-up of patients with excellent response to 
initial therapy.
Item 15  Follow-up of patients with persistent structural 
disease or biochemical disease.
Item 16  Fo l low-up  o f  pa t i en t s  t r ea ted  wi t h 
lobo-isthmectomy.
851Journal of Endocrinological Investigation (2018) 41:849–876 
1 3
Item 17  Is there an indication for rhTSH in the prepara-
tion of patients undergoing radioiodine therapy 
for metastatic disease?
Item 18  Radioiodine treatment of metastatic disease: 
standard activities vs. dosimetry, maximal cumu-
lative activity, and frequency of treatment courses.
Item 19  “Empiric” treatment with radioiodine in Tg posi-
tive/WBS negative patients: still an indication?
Item 20  Adverse events of radioiodine therapy.
Item 21  Definition of RAI resistant disease.
Item 22  What is the role of systemic therapy (kinase inhib-
itors and conventional chemotherapy) in treating 
metastatic DTC?
Item 23  l-Thyroxine therapy after total thyroidectomy or 
lobectomy.
Item 24  Legal issue in the management of thyroid cancer.
Item 1: Selection of thyroid nodules to be 
submitted to cytological evaluation
Recommendation statement
In thyroid US reports, a conclusive score that stratifies thy-
roid nodules on the basis of risk of malignancy should be 
provided according to the following Ultrasound (US) Rating 
of the Risk of Malignancy:
Class 1. Low-risk thyroid lesion:
Purely cystic nodules have virtually no risk. Mostly cystic 
(> 80%) nodules with reverberating artifacts have very 
low risk (< 1%).
Spongiform, isoechoic or hyperechoic nodules not associ-
ated with suspicious US findings (expected risk of malig-
nancy, about 1%).
Class 2. Intermediate-risk thyroid lesion:
Slightly hypo- or isoechoic nodules with ovoid-to-round 
shape and smooth or ill-defined margins. May be pre-
sent: intranodular vascularization, macro- or continuous 
rim calcifications, increased stiffness at elastography or 
hyperechoic spots of uncertain significance (expected risk 
of malignancy, 5–15%).
Class 3. High-risk thyroid lesion:
Nodules with at least one of the suspicious findings: 
marked hypoechogenicity, spiculated or microlobulated 
margins, micro-calcifications, taller-than-wide shape, 
extrathyroidal growth or lymphadenopathy (expected risk 
of malignancy, 50–90%, according to the presence of one 
or more suspicious findings).
Recommendation for FNA
Low‑US‑risk thyroid lesions (Class 1)
(a) US-guided FNA is recommended for nodules ≥ 20 mm 
in diameter only when symptomatic, increasing in size, 
associated with high-risk factors, or before surgery or 
local percutaneous therapy.
(b) Hyperfunctioning thyroid nodules: FNA is usually not 
recommended.
Intermediate‑US‑risk thyroid lesions (Class 2)
(a) US guided FNA is recommended for nodules ≥ 20 mm. 
For smaller nodules, clinical monitoring is indicated.
High‑US‑risk thyroid lesions (Class 3)
(a) Diameter 5–9 mm: either US-guided FNA sampling 
or US monitoring on the basis of clinical setting and 
patient preference. US-guided FNA is recommended 
for subcapsular, posterior or paratracheal lesions, or in 
case of suspicious lymph nodes, extrathyroid spread, 
clinical thyroid cancer risk factors.
(b) Diameter ≥ 10 mm: US-guided FNA is recommended.
Narrative of the recommendation
Nowadays, most thyroid nodules are detected incidentally 
in euthyroid subjects and are not associated with clinical 
symptoms. Thus, the major task in their management is to 
exclude the minority of cases (about 5%) that correspond to 
a malignant lesion. Thyroid US, clinical features and patient 
age are the basis for selecting thyroid nodules that deserve 
US-guided fine-needle aspiration (FNA) cytology [1]. Thy-
roid scintigraphy is usually not required and should be per-
formed only in those patients with low TSH levels to dem-
onstrate potential areas of functional autonomy, although 
in sporadic cases, thyroid autonomy may be present even 
with low–normal TSH values, particularly in multinodu-
lar goiters. Currently, US features are more relevant than 
the size of the nodule to define the risk of cancer and the 
strength of indication to FNA.
In the selection of nodules for US-guided FNA, however, 
a correct balance between the risk of a missed diagnosis of 
low-risk cancer and that of a large-scale use of inappropriate 
invasive procedures should be considered.
A higher probability of malignancy is associated with the 
following findings: nodule height greater than width, micro-
calcifications, irregular margins, and marked hypoecho-
genicity. Solid nodule structure, intranodular vascular 
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signals, and mild hypoechogenicity have a lower predictive 
value. As in a part of thyroid carcinomas, the US signs pre-
dictive of malignancy are lacking, and the absence of clearly 
suspicious features is not diagnostic for a benign lesion.
Size and number
Nodule volume is not a predictive factor for malignancy even 
if the risk of cancer and of a potentially more advanced dis-
ease is slightly higher in nodules > 4 cm. Thus, small sus-
picious nodules (< 10 mm) may be considered for either 
US-guided FNA or US follow-up, while incidental thyroid 
lesions with a diameter ≤ 5 mm should only be followed over 
time.
Volume increase is not indicative of malignancy. Rapid 
growth is observed only in the infrequent highly aggres-
sive tumors and is generally associated with suspicious US 
findings.
Nodule volume assessment by the ellipsoid formula 
(longitudinal diameter × transverse diameter × anteropos-
terior diameter × π/6) should be used for follow-up. A 20% 
increase in two diameters or 50% of the volume should 
be used as the minimum threshold for significant nodule 
growth.
Structure and echogenicity
Most carcinomas are visualized as hypoechoic solid lesions, 
but about half of benign thyroid nodules show a similar 
appearance. Therefore, mild hypoechogenicity is a sensi-
tive but poor specific predictor of malignancy. Marked 
hypoechogenicity is a highly suspicious finding.
Predominantly cystic thyroid nodules are almost never 
malignant, although occasional cases have been reported.
Iso- or hyperechoic thyroid lesions characterized by the 
aggregation of multiple microcystic components that com-
prise more than 50% of the volume (“spongiform nodules”) 
are nearly always benign.
Margins and shape
The majority of benign thyroid lesions have a regular round 
to oval profile. A taller-than-wide shape and the presence 
of ill-defined margins deserve attention, while irregular, 
spiculated, or lobulated contours are highly specific signs 
of malignancy.
A regular hypoechoic halo is a typical finding in benign 
nodules, while a thick, irregular or incomplete, hypoechoic 
halo due to inflammatory or necrotic changes may be 
observed in differentiated thyroid carcinoma.
Calcifications
Micro-calcifications are revealed as ≤ 1 mm hyperechoic 
spots without posterior shadowing (unless in cluster). The 
specificity for malignancy of true micro-calcifications is 
elevated, but, unfortunately, their sensitivity is rather low. 
Intranodular hyperechoic spots that are not due with cer-
tainty to micro-calcifications should be reported as “hyper-
echoic spots of uncertain significance” to prevent an inap-
propriate upgrading of the risk of PTC.
Macrocalcifications are generally due to regressive 
changes, but should be considered as a potential risk factor.
Peripheral (“rim”) calcifications are sometimes found in 
nodular goiters. A discontinuity of the egg-shell structure 
due to extrusive growth of hypoechoic tissue may be predic-
tive of malignancy.
Vascularity
Color- and power-Doppler evaluation of thyroid nodules pro-
vides only complementary data. Malignant lesions (mainly, 
follicular thyroid carcinoma) may demonstrate a rich intran-
odular pattern, but this finding may be present in benign 
nodules as well. A scanty vascularity is observed in most 
benign nodules, but PTMC may appear as avascular lesions 
as well.
Elastography
The stiffness of thyroid nodules during the delivery of an 
impulse by the US probe has a good sensitivity for thyroid 
carcinoma with a high negative predictive value. Elastog-
raphy may be an additional complementary diagnostic tool 
used in some centers, but current evidence does not allow to 
recommend its use in routine practice.
Further suspicious US findings
Growth of thyroid nodules beyond the capsule and infil-
tration of the trachea or recurrent laryngeal nerves are 
infrequent but threatening features that warrant cytologic 
evaluation.
Enlarged lymph nodes with cystic changes, micro-cal-
cifications, and increased echogenicity (thyroid tissue-like 
appearance) are highly suspicious. Rounded appearance, 
chaotic hypervascularity, and the absence of hilum are less 
specific US features of malignancy [2].
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Item 2: Based on cytology result, 
when is thyroid surgery indicated?
Recommendation statement
Non‑diagnostic nodules (TIR 1)
(a) In nodules solid at US, repeat FNA is recommended. 
Clinical and US follow-up may be considered for non-
diagnostic cystic or predominantly cystic nodules (TIR 
1C) without suspicious clinical or US features.
(b) Consider diagnostic surgery for persistently non-diag-
nostic solid nodules if suspicious clinical and US fea-
tures are present and the size is greater than 1 cm.
Benign nodules (TIR 2)
(a) Most TIR 2 nodules do not require treatment.
(b) Surgery is recommended in the presence of compres-
sive symptoms.
(c) The preferred extent of surgical resection for benign 
uninodular goiter is lobectomy, while for bilateral mul-
tinodular goiter is total thyroidectomy.
Low‑risk indeterminate nodules (TIR 3A)
(a) We recommend repeat FNA and consultation with an 
experienced cytopathologist.
(b) Consider conservative management in the case of 
favorable clinical and US criteria, while thyroid lobec-
tomy may be considered in the other cases. Total thy-
roidectomy may be considered depending on the clini-
cal setting, coexistence of contralateral nodules and 
patient preference.
High‑risk indeterminate lesions (TIR 3B)
(a) Surgery is recommended in most cases
(b) Thyroid lobo-isthmectomy is recommended. Total thy-
roidectomy may be performed, depending on the clini-
cal situation, coexistence of other thyroid nodules, and 
patient preference.
(c) Consider close clinical follow-up in a minority of cases 
with favorable clinical and US features, after discussion 
of treatment options with the patient.
(d) For both TIR3A and TIR3B categories, mutational 
analyses (at least BRAF and RAS genes), if accessible, 
is of added value for the diagnosis of malignancy, when 
mutations are detected.
Suspicious nodules (TIR 4)
(a) Surgery is recommended in most cases (see TIR 5). 
Additional techniques (molecular biology) for a better 
characterization may be considered in selected cases.
Malignant nodules (TIR 5)
(a) Surgery is recommended. The extent of surgery is total 
thyroidectomy in most cases, but lobectomy may be 
considered for intrathyroidal, uni-or multiple unilateral 
small nodules.
(b) A close follow-up without surgery may be considered 
in selected low-risk patients (see “Item 5”) with small 
nodules and in intermediate-risk fragile subjects, after 
careful discussion with the patient. The rationale for 
this statement is based on the very favorable outcome 
even without surgery.
(c) For anaplastic or medullary thyroid carcinoma, meta-
static lesions, and primary thyroid lymphoma further 
multidisciplinary diagnostic work-up is recommended.
Narrative of the recommendation
The decision for surgery resides primarily on the result of 
cytology, but also on other considerations such as the size 
of the nodule, the age of the patient and the presence of 
comorbidities. In this consensus, the Italian classification 
for cytology [3] is followed that subdivides TIR 3 in two 
categories TIR 3A and TIR 3B, with different risks of malig-
nancy, similar to the subdivision in AUS/FLUS-FN/SFN of 
the Bethesda [4] and to the Thy 3 ‘‘a’’ and ‘‘f’’ of British 
Thyroid Association systems [5]. Yet, at variance with these 
two reference systems, in the Italian classification, the cat-
egory TIR 3B includes those cases with ‘‘mild/focal nuclear 
atypia’’ that have a higher risk of malignancy.
Non‑diagnostic nodules (TIR 1)
Non-diagnostic FNA specimens often result from cystic 
(TIR1C) or mixed nodules that are mostly benign. However, 
solid nodules sometimes yield repeatedly non-diagnostic 
results by FNA. These nodules should be considered for 
surgery in the presence of clinical or US suspicious findings 
or in the case of growth (> 20% in 2 dimensions). Consider 
core needle biopsy in experienced centers.
Benign nodules (TIR 2)
Most nodules with benign cytology do not require treatment. 
The expected risk of malignancy is below 3%. Surgery is 
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indicated in nodules of large size (> 4 cm) in young patients 
and in the presence of pressure symptoms. Surgery should 
also be considered in nodules that develop suspicious US 
changes or increase in volume and become symptomatic. 
The preferred extent of resection is lobectomy for benign 
uninodular goiter and total thyroidectomy for bilateral 
multinodular goiter. Surgery may be considered for benign 
hyperfuctioning thyroid nodules > 3 cm, especially in young 
patients. Local treatment techniques (laser or radiofrequency 
ablation) may be considered for selected cystic lesions or 
symptomatic solid nodules without suspicious clinical and 
US findings. In this case, a second confirmatory benign 
FNAC should be obtained.
Indeterminate lesions (TIR 3)
Management of indeterminate thyroid nodules should be not 
only based on their cytologic sub-classification, but also on 
clinical data, US findings, and, possibly, mutational analy-
sis. The use of molecular tests, however, is still expensive 
and should be restricted to specialized centers for selected 
patients. Interdisciplinary consultation is recommended in 
the management of these cases, and the diagnostic and thera-
peutic options should be discussed with the patient.
1. Low-risk indeterminate lesions (TIR 3A)
The expected risk of malignancy is 5–15%. Close fol-
low-up is suggested as the preferential option in most cases. 
Conservative management is supported by favorable clini-
cal criteria, based on personal and family history and small 
size of the lesion, but the most important factor in decision 
making is represented by low-risk US features. A repeat 
FNA reviewed by an experienced cytopathologist is rec-
ommended, but may still not offer conclusive information. 
Patients with suspicious clinical or US findings should pref-
erentially be treated with lobectomy. Total thyroidectomy 
may be considered depending on the clinical setting, coexist-
ence of contralateral nodules and patient preference.
2. High-risk indeterminate lesions (TIR 3B)
The expected risk of malignancy is 15–30%. Repeat FNA 
of nodules classified as follicular neoplasm is not generally 
recommended, because it does not provide additional infor-
mation for management. Surgical excision of the lesion with 
histologic examination should be performed in most cases. 
In patients with favorable clinical and US features, a close 
clinical follow-up without immediate diagnostic surgery may 
considered.
Patients are preferentially treated with lobectomy. Frozen 
sections are usually not recommended, but may be useful to 
decrease the risk of subsequent completion thyroidectomy in 
the scenario of cancer diagnosis. Total thyroidectomy may 
be performed on the basis of the clinical setting, coexistence 
of contralateral thyroid nodules, and patient preference.
Suspicious nodules (TIR 4)
The rate of histologically confirmed malignancy in these 
cases is about 60–75%, papillary carcinoma being the most 
frequent histologic type. Indications for surgery are quite 
similar to nodules with TIR 5 cytology.
Malignant nodules (TIR 5)
This category includes cases with a conclusive cyto-
logic diagnosis of malignant neoplasm. TIR 5 cytological 
diagnosis accounts for 2.7–5% of the FNA, with a risk of 
malignancy greater than 98%. Treatment options should 
be discussed with the patient. Surgical excision should be 
recommended and its potential complications discussed. 
The surgical approach and its extent should be planned 
according to the clinical setting and the imaging findings. 
For large tumors with pre-surgical evidence of local metas-
tases, total thyroidectomy and removal of lymph nodes are 
indicated. For patients with thyroid cancer > 1 and < 4 cm 
without extra-thyroidal extension or clinical evidence of 
lymph node metastases, the initial surgical procedure can 
be either total thyroidectomy or lobectomy, depending on the 
willingness of the specialist and the patient to perform post-
surgical radioiodine ablation. A close clinical follow-up may 
be offered to patients with very low-risk tumors (papillary 
microcarcinomas with no clinical evidence of extra thyroid 
spread or metastases) and to elderly patients with inciden-
tally discovered papillary cancer, who are at high surgical 
risk and have no evidence of extra thyroid spreading.
Item 3: What is the role of pre‑operative 
staging with diagnostic imaging 
and laboratory tests?
Recommendation statement
(a) Accurate pre-operative staging of DTC is based on neck 
US and it is mandatory in all patients to carry out the 
most appropriate surgical treatment.
(b) Suspicious neck lymph nodes should be submitted to 
FNAC complemented with thyroglobulin measurement 
in the needle washout (FNA-Tg).
(c) In patients presenting with US and/or clinical evidence/
suspicion of locally advanced thyroid carcinoma, cross-
sectional imaging studies (e.g., CT and/or MR) are rec-
ommended for accurate surgical planning.
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(d) Routine serum Tg/TgAb measurement before surgery 
is not recommended.
(e) Serum calcitonin (CT) measurement before surgery is 
recommended.
Narrative of the recommendation
Lymph node metastases occur quite frequently in patients 
with DTC; therefore, pre-surgical staging has a strategic role 
to optimize surgical cure [1, 5–8]. Moreover, in patients with 
clinically low-risk DTC, the information obtained through 
the pre-surgical staging may be critical to define the most 
appropriate treatment option, which may encompass active 
surveillance as well as conservative surgery (i.e., lobec-
tomy) or total thyroidectomy with or without central neck 
dissection.
US is the more sensitive imaging technique for the exami-
nation of the thyroid gland as well as the neck lymph nodes, 
thus playing a pivotal role in the pre-operative staging of 
patients candidate to surgical treatment of DTC. US reso-
lution in detecting minimal extrathyroidal extension of the 
tumor, as well as microscopic neoplastic foci is less than 
optimal. In addition, US sensitivity in detecting lymph node 
metastases in the central compartment prior to thyroidec-
tomy is quite low. Notwithstanding these limitations, US-
based staging of the disease should aim to provide the fol-
lowing information:
• site and size of the primary tumor and of suspicious 
lymph nodes;
• evidence of tumor multifocality/bilaterality and of 
extrathyroidal spreading;
• other neck masses and gross vascular abnormalities.
The above-mentioned US signs and patterns which sug-
gest malignancy of neck lymph nodes do not have absolute 
specificity. The measurement of thyroglobulin on needle 
washout (FNA-Tg) is a valuable diagnostic aid, reducing 
the risk of non-diagnostic results due to cytological sam-
ples of poor quality. FNA-Tg levels in metastatic thyroid 
lymph nodes are usually exceedingly high (> 500–1000 ng/
mL), and allow a clear-cut diagnosis; nevertheless, FNA-Tg 
results should always be weighed against the levels of circu-
lating serum Tg. In most cases, the presence of serum anti-
Tg antibodies does not interfere with FNA-Tg measurement.
In a minority of cases, DTC may present with signs and 
symptoms suggesting invasion of deep neck structures and/
or mediastinum, which cannot be adequately visualized by 
neck US. Cross-sectional imaging of the neck, mediastinum, 
and lung is required in the following settings:
• primary tumor and/or loco-regional metastases only par-
tially imaged by neck US;
• voice changes, dysphagia, dyspnea or other symptoms of 
mediastinal extension;
• rapidly enlarging palpable and firm neck masses.
When CT scan with iodine-containing contrast medium 
is performed, a 1 month-interval between CT study and 131I 
administration is required. Patients presenting with signs and 
symptoms suggesting tumor invasion into the airways and/
or the digestive tract should undergo tracheobronchoscopy 
and/or esophagoscopy. Screening for other sites of distant 
metastases is not recommended on routine bases.
The measurement of serum Tg and TgAb levels prior to 
thyroidectomy does not provide any useful information for 
disease staging. Increased serum Tg levels (when present) 
reflect the size of the normal thyroid and of the nodule(s) 
and the functional thyroid status rather than the nature of 
the nodule(s).
Serum calcitonin (CT) measurement is useful to reveal 
medullary thyroid cancer. Not all authors recommend calci-
tonin measurement in all the nodules; thus, a good compro-
mise may be to advocate CT measurement at least in patients 
undergoing surgery for suspicious cancer or in patients with 
multinodular goiter.
Item 4: When thyroidectomy is indicated 
which strategy should be performed: total 
or lobo‑isthmectomy?
Recommendation statement
(a) Thyroid lobo-isthmectomy alone is an adequate initial 
surgical treatment for patients with suspicious can-
cer ≤ 1 cm, clinically limited to one lobe, with no evi-
dence of extrathyroidal extension or metastatic disease 
to nodes (cN0b) or prior head and neck irradiation.
(b) Total thyroidectomy is recommended with at least one 
of the following parameters: patients with differenti-
ated thyroid carcinoma > 4 cm, unilateral or multifocal 
disease, with at least one of the following: clinically 
(or intraoperative) detected cervical nodal metastases, 
gross extrathyroidal extension or metastatic disease to 
distant sites.
(c) Lobo-isthmectomy or total thyroidectomy may be 
proposed to patients with differentiated thyroid carci-
noma > 1 and < 4 cm without clinical (or intraoperative) 
evidence of extrathyroidal extension and lymph node 
metastases (N0b). Total thyroidectomy may be pre-
ferred to enable radioiodine treatment and to enhance 
follow-up accuracy, or for preference of the patient.
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Narrative of the recommendation
Extension of thyroidectomy for patients with differentiated 
thyroid carcinoma is still matter of debate. Many guidelines 
have supported total thyroidectomy as the primary initial 
surgical treatment option for nearly all differentiated thyroid 
carcinomas greater than 1 cm with or without evidence of 
nodal or distant metastases. This approach was based on 
retrospective data suggesting that bilateral surgical proce-
dure would decrease recurrence rates [9]. Recent data have 
demonstrated that in properly selected low-risk patients, the 
overall survival and cause specific survival rates are similar 
following unilateral or bilateral surgery [10, 11].
Considering recent evidence patients and surgeons should 
carefully balance the relative benefits and risks of total thy-
roidectomy vs. thyroid lobo-isthmectomy. Most of these can-
cers are not aggressive and could be treated with a unilateral 
procedure only, because the percentage of complications for 
total thyroidectomy is not irrelevant, while clinical surveil-
lance and the possibility of second step surgery can reas-
sure both surgeon and patient about the final outcome. This 
choice should include surgeon volume (that is, referral to 
dedicated thyroid surgeons) due to the relationship between 
high-volume thyroid surgical center and patient outcomes
Item 5: No intervention for papillary thyroid 
microcarcinoma
Recommendation statement
(a) Even if surgery is the treatment of choice, “no imme-
diate intervention” and active surveillance may be 
considered for very low-risk PTMC in the following 
setting:
1. patients at high surgical risk;
2. patients who refuse surgical treatment;
3. patients willing to enter into controlled clinical tri-
als.
(b) A personal decision making is recommended as well as 
an accurate discussion with the patient to explain pro 
and cons of the active surveillance vs. surgical treat-
ment.
(c) A careful clinical and cytological evaluation of risk fac-
tors for aggressive behavior or recurrence of PTMC is 
recommended. A repeated “neck” sonographic evalu-
ation after cytological suspicion of PTMC should be 
the first step to be carried out to exclude the presence 
of suspicious lymph nodes.
Narrative of the recommendation
PTMC has an excellent prognosis and its natural history dis-
plays a very low progression [12]. However, since a minority 
of observed PMTC over time showed increases tumor size or 
the appearance of lymph node metastases, a long-term active 
surveillance is recommended.
Clinical patient history, physical and US examination, and 
molecular investigation cannot really distinguish the small 
subgroup of PTMC at risk of developing local or distant 
metastases from the majority of PTMC associated with an 
indolent course.
In case of choice of “active surveillance” of PTMC, neck 
ultrasound should be repeated every 6 months in the first 
2 years and once a year thereafter: a significant increase in 
size of the nodule or the evidence a suspicious lymph node 
not present at the previous controls are the main reasons to 
re-thing the therapeutic strategy.
Risk factors for aggressive behavior and recurrence of 
PTMC include: previous neck irradiation; extra-thyroidal 
extension at US; subcapsular or posterior localization of 
PTMC; multifocal or bilateral tumor; coexistence of Graves’ 
disease; suspicious lymph node involvement; aggressive 
cytological features; and BRAF mutation (if available).
Item 6: Indication for completion 
thyroidectomy after lobectomy
Recommendation statement
(a) Completion thyroidectomy is indicated to those patients 
for whom a total thyroidectomy would be suggested as 
the initial surgical treatment in case of primary diag-
nosis of differentiated thyroid cancer.
(b) Completion thyroidectomy is mandatory for differen-
tiated thyroid carcinoma > 4 cm, or any differentiated 
thyroid carcinoma with extrathyroidal extension and/or 
with histological evidence of lymph node metastases or 
aggressive variants.
(c) In the other cases, completion thyroidectomy is not rou-
tinely indicated, but the final decision should be taken 
based on a tailored strategy involving a careful discus-
sion with the patient.
Completion thyroidectomy is not indicated for a final his-
tology of NIFT-P [13].
Narrative of the recommendation
Since differentiated thyroid carcinomas can be managed 
with either lobo-isthmectomy or total thyroidectomy, a com-
pletion thyroidectomy is not always required.
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Every case is crucial to weigh the relative advantages 
and disadvantages of thyroid lobectomy with completion 
thyroidectomy vs. initial total thyroidectomy. Risk group 
stratification and post-operative risk-adapted evaluation is 
mandatory. The multidisciplinary team may choose the treat-
ment of choice evaluating also patient’ s preferences and 
follow-up opportunities.
The surgical risks of two-stage thyroidectomy are similar 
to those for a total thyroidectomy, but this is true only in 
specialized centers [14]. The accuracy of the first surgery is 
crucial to minimize the risk of re-operation. In particular, re-
operation is safer in the presence of not dissected contralat-
eral thyroid lobe when thyroid lobectomy was carried out 
en bloc with thyroid isthmus. Nonetheless, the evidence of 
inferior laryngeal nerve palsy following thyroid lobectomy 
calls for strong caution in deciding to perform completion 
thyroidectomy.
Patients with low-risk tumors must undergo surveillance 
imaging to detect remnant gland recurrence. In experienced 
hands, ultrasound is the tool of choice to follow-up these 
patients, ensuring an adequate diagnostic accuracy. Thus, 
patients can be treated with completion thyroidectomy if 
necessary at a later date, avoiding unnecessary surgery and 
limiting the risk of post-operative complications.
Item 7: The role of central and lateral 
compartment neck dissection 
in the management of DTC
Recommendation statement
(a) Prophylactic central compartment neck dissection 
(CCND) is not routinely indicated.
(b) CCND is appropriate for patients with differenti-
ated thyroid carcinomas in the presence of clinically 
involved lymph nodes (cN1) either in the central com-
partment or in the lateral neck.
(c) Lateral neck dissection is appropriate for patients with 
differentiated thyroid carcinomas in the presence of 
metastatic lymph nodes (cN1) in the lateral neck.
(d) Intraoperative surgeon judgement is critical to decision 
making on whether central neck dissection is to be per-
formed.
Narrative of the recommendation
Given the high incidence of occult nodal metastases in papil-
lary thyroid carcinoma (PTC), prophylactic CCND has been 
proposed as the initial management of these tumors. Never-
theless, the role of prophylactic CCND in the management 
of thyroid cancer remains controversial [15–17].
The potential benefits of include:
• eliminating a possible source of recurrence and prevent-
ing the morbidity of revision surgery;
• increasing the accuracy of disease staging for radioactive 
iodine therapy;
• improving the accuracy of thyroglobulin surveillance and 
long-term follow-up.
While occult node positivity is quite common in PTC, 
these occult metastases tend to be small in size and number, 
with no extranodal extension, and a median risk of recur-
rence of only 2% at 5 years. The comparability in oncologic 
outcome between patients who undergo prophylactic CCND 
and those who do not confirms the indolent biologic behavior 
of subclinical nodal disease [17]. In addition, meta-analyses 
seem to show that the presence of occult central nodal metas-
tases is not a significant predictor of recurrence nor did pro-
phylactic CCND offer improved local control [18].
On the other hand, it should be considered that CCND 
increases the risk of hypoparathyroidism and, with a lower 
degree of evidence, of recurrent nerve palsy when compared 
to total thyroidectomy alone.
Prophylactic ipsilateral central compartment neck dissec-
tion, including pre-laryngeal, pretracheal, and paratracheal 
nodal basins on the side of the tumor, with frozen section 
examination, could be proposed in selected patients [19].
Item 8: The need for a complete histological 
and cytological report
Recommendation statement
1. Histology (see Appendix 1):
(a) The thyroid specimen should accurately describe 
the weight (or the measurements of the lobes), the 
characteristics of the nodule(s), and the presence 
of periglandular fat.
(b) The histological report should include the pre-
dominant histotype and, if present, only a minor 
component of either an aggressive variant (diffuse 
sclerosing variant, tall/columnar cell, hobnail, 
solid) or a less differentiated tumor type (insular, 
trabecular, and anaplastic).
(c) The histology should also report the presence of 
capsular (thyroid and tumor) invasion, of vascular 
infiltration (no. of involved vessels), additional neo-
plastic foci (size and site) and lymph nodes (even-
tual micro-metastases < 2 mm and size of the larger 
node).
(d) Immunohistochemical and molecular analyses, 
when performed, should be reported or there 
should be a reference to an additional report (e.g., 
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molecular studies). TNM report should follow the 
VIII edition of AJCC/UICC [20].
2. Cytology:
(a) The cytological report should specify the type of 
technique used to obtain the sample (FNAC, with 
or without US guide or other) and the size of the 
needle used (Gauge).
(b) Essential clinical information must be included 
with the sample such as the structure of lesion 
(cystic vs. solid), the location (isthmus vs. lobes), 
the number of lesions analyzed and their size, the 
functional status, and the sonographic pattern (see 
“Item 1” and ATA guidelines).
(c) Indicate the method used to process the sample 
(conventional smear vs. liquid based cytology).
(d) Use the Italian reporting system to classify the 
lesions:
TIR 1 non-diagnostic (risk of malignancy not 
defined).
TIR 1C cystic (< 10%).
TIR 2 negative for malignant cells/benign (< 3%).
TIR 3A low-risk indeterminate lesion (5–10%).
TIR 3B high-risk indeterminate lesion (20–30%).
TIR 4 suspicious of malignancy (60–80%)
TIR 5 positive for malignant cells (> 95%).
Narrative of the recommendation
Aggressive variants of papillary carcinoma.
The variants with more unfavorable outcomes are the tall 
cell, columnar cell, and hobnail variants. Their knowledge 
may contribute to risk stratification. At least 30% of “tall 
cell”, according to Ganly et al. [21] or 10%, according to 
Dettmer et al. [22], should be present to diagnose the tall 
cell variant. This variant is associated with higher rate of 
lymph node metastasis and poorer survival independently 
of patient age, tumor size and stage [23]. The columnar cell 
variant is characterized by predominance of columnar cells 
with pronounced nuclear stratification. These tumors have a 
higher risk of distant metastases and tumor-related mortality.
Papillary carcinoma with prominent hobnail features is 
a rare, recently described variant characterized by the pre-
dominance of cells with a hobnail appearance with apically 
placed nuclei and bulging of the apical cell surface [24]. It 
is associated with frequent distant metastases and increased 
risk of tumor-related death.
Other variants of papillary carcinoma, such as the solid 
variant and diffuse sclerosing variant, have been traditionally 
associated with a less favorable outcome, although the data 
remain conflicting.
The solid variant is more frequently associated with distant 
metastases that are present in about 15% of cases, and with 
a slightly higher mortality rate, which was 10–12% in two 
studies with 10 and 19 years of average follow-up [25]. The 
solid variant of papillary carcinoma should be distinguished 
from poorly differentiated thyroid carcinoma, with which it 
shares the insular, solid, and trabecular growth patterns. The 
distinction is based primarily on the preservation of nuclear 
features and lack of necrosis and high mitotic activity in the 
solid variant, as outlined by the Turin diagnostic criteria for 
poorly differentiated thyroid carcinoma [26, 27].
The prognostic implication of the diffuse sclerosing vari-
ant of papillary cancer remains controversial. This variant 
is characterized by diffuse involvement of the thyroid gland 
and it has lower disease-free survival [28] and a higher rate 
of local and distant metastases at presentation [29].
Lymph nodes
The number of involved LNs, the size of the largest metastatic 
focus within the lymph node, the location of the lymph nodes, 
and the presence of extranodal extension are all determinant 
of the risk of recurrence. Sugitani et al. [30] demonstrated that 
risk of recurrence at 10 years following total thyroidectomy and 
neck dissection without RAI ablation was significantly higher in 
patients with pN1 disease with the largest metastatic LN > 3 cm 
(27%) than in patients with pN1 disease < 3 cm (11%). The risk 
of recurrence was significantly higher in patients with > 5 LN 
metastases (19%) that in those with < 5 LN metastases (8%). 
Consideration should also be given to reporting the specific his-
tologic features of the LN metastases (e.g., specific histologic 
variant and the presence of tumor necrosis/mitosis). Based on 
these features, it has been proposed to differentiate lower risk 
N1 disease (Clinically N0, Micro-metastases, or less than five 
small lymph nodes, with < 5% risk of recurrence) from higher 
risk N1 disease (cN1, lymph nodes > 3 cm or > 5 metastatic 
nodes, with > 20% risk of recurrence).
Item 9: Post‑surgical thyroid ablation 
with radioiodine: routine or selective 
indication
Recommendation statement
(a) The indication to post-surgical thyroid ablation with 
radioiodine should be established both on the basis of 
the AJCC/UICC staging (VIII edition) and the Initial 
Risk Stratification System proposed by ATA, useful to 
predict the risk of mortality and of disease recurrence/
persistence, respectively.
(b) The indication should also be based on the post-oper-
ative disease status evaluated by serum Tg (on thy-
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roid hormone therapy or after TSH stimulation) and 
neck US. In selected cases, other imaging procedures 
(including diagnostic RAI WBS) may be indicated.
(c) In patients with ATA low-risk (T1a-b, N0-X, M0-X), 
RAI remnant ablation is not generally recommended. 
However, consideration of specific features could lead 
to consider RAI remnant ablation in individual patients.
(d) In patients with intermediate or low-to-intermediate 
risk (T1-2, N1a–N1b, M0-X), RAI remnant ablation 
should be considered, particularly in patients with 
adverse features such as advanced age, larger tumors, 
macroscopic or clinically evident lymph nodes or the 
presence of extranodal extension, or aggressive histol-
ogy or vascular invasion.
(e) In patients with high risk or intermediate to high risk 
(T3-4, any N, any M), RAI ablation is routinely recom-
mended.
Narrative of the recommendation
When deciding whether to perform or not thyroid ablation, 
two concept should be taken into account:
• Even if it has been decided not to perform RAI ablation 
immediately after surgery, it can be done at any time dur-
ing the follow-up if the opportunity/necessity comes up.
• Post-operative serum Tg and neck US have been demon-
strated to be useful in predicting the result of 131-I WBS 
and when basal serum Tg or TSH-stimulated Tg are unde-
tectable or < 5 ng/mL, respectively, associated with a nega-
tive neck US the probability to have local or distant metas-
tases is negligible and thus remnant ablation can be avoided.
Our statement is based on the following consideration:
• In low-risk DTC patients, there is little evidence to sug-
gest that thyroid ablation may improve the very low risk 
of disease-specific mortality and to have an effect on the 
low rate of recurrence [31–33]. Besides, it is not demon-
strated that delayed diagnosis and treatment of persistent 
disease may decrease the chance of cure. Retrospective 
multicenter studies and prospective data did not show sig-
nificant effect of thyroid ablation on overall or disease-free 
survival, both using multivariate and stratified propensity 
analysis. In systematic reviews, the majority of studies did 
not show a significant effect of thyroid ablation in reducing 
thyroid cancer-related death, and conflicting findings have 
been provided regarding disease recurrence. The majority 
of the studies suggest that RAI adjuvant therapy is unlikely 
to improve disease-specific or disease-free survival in uni- 
or multifocal papillary microcarcinoma, in the absence of 
other higher risk features. However, only the results from 
prospective randomized controlled trials, at moment in 
progress, should definitely indicate which patients with 
low-risk DTC may or may not benefit from post-operative 
RAI.
• For intermediate-risk DTC, the greatest potential benefit 
(improved overall survival) of the thyroid ablation are 
observed in patients with aggressive papillary thyroid 
cancer histologies, primary tumor > 4 cm, evidence of 
extrathyroidal extension, increasing volume of nodal dis-
ease, lymph node disease outside the central neck (N1b 
disease), lymph nodes > 1 cm in diameter and advancing 
patient age (> 45 years) [34]. A systematic review evalu-
ating the benefit of RAI in intermediate-risk patients, 
reported a significant benefit of RAI treatment in improv-
ing overall and disease-specific survival as well as dis-
ease-free survival in about half of the non-randomized 
studies. However, more research is needed to understand 
the therapeutic efficacy of RAI in various subgroups of 
patients in the intermediate-risk category.
• Data from prospective multicenter studies on papillary or 
follicular high-risk DTC patients suggest that post-surgical 
RAI therapy is associated with improved overall survival 
and disease-specific mortality. The overall survival in FTC 
patients with iodine-positive distant metastases is more than 
doubled in patients receiving post-surgical RAI treatment.
Item 10: Preparation for thyroid ablation 
and selection of the most appropriate 
activity
Recommendation statement
Preparation for radioiodine ablation
(a) In patients with low and intermediate ATA risk DTC 
without extensive lymph node involvement, preparation 
with recombinant human TSH (rhTSH) stimulation is 
equally effective compared to thyroid hormone with-
drawal (THW) but with the advantage of preserving the 
quality of life.
(b) In patients with ATA high-risk DTC and high risk of 
disease-related mortality and morbidity, more con-
trolled data from long-term outcome studies are needed 
to recommend the routine use of rhTSH
(c) In patients with DTC of any risk level presenting with 
significant medical or psychiatric comorbidity who 
cannot tolerate hypothyroidism or are unable to obtain 
an elevation of TSH by THW, rhTSH preparation 
should be considered.
(d) In preparation for thyroid ablation, avoidance of iodine-
containing drugs or iodinated contrast agents is manda-
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tory. A low iodine diet avoiding preserved fish, sushi, 
seaweed for 1–2 weeks should be recommended
(e) Except for patients with suspected iodine contamination, 
the routine measurement of urine iodine excretion before 
RAI thyroid remnant ablation may not be necessary.
Selection of the most appropriate activity of radioiodine 
for remnant ablation
(a) In patients with low-risk or intermediate-risk thyroid 
cancer, a low administered activity of radioiodine (30–
50 mCi) for remnant ablation is generally favored being 
low activities as effective as high activities in obtain-
ing complete ablation. Higher administered activities 
(100 mCi or more) should be considered for patients 
at high risk of persistent/recurrent disease, when the 
administration is intended in terms of adjuvant therapy 
or for patients submitted to less than a total or near-total 
thyroidectomy.
Narrative of the recommendation
A precondition to the radioiodine administration for thyroid 
remnant ablation is an adequate elevation of serum thyroid-
stimulating hormone (TSH). Serum TSH elevation may be 
obtained using two methods: (a) thyroid hormone with-
drawal and (b) administration of exogenous rhTSH.
(a) If thyroid hormone withdrawal is planned, levothy-
roxine (LT4) should be withdrawn for 3–4 weeks. If 
 LT4 is withdrawn for 6 weeks, triiodothyronine (LT3) 
may be substituted for LT4 in the initial 4 weeks, and 
withdrawn in the last 2 weeks. Serum TSH should be 
measured prior to radioiodine administration to verify 
the appropriated degree of TSH elevation.
(b) When using rhTSH, the recommended dosage is 
0.9 mg given by two i.m. injections to the buttock in 
the 2 days preceding the radioiodine administration. 
Routine measurement of serum TSH levels is not rec-
ommended. rhTSH is currently approved in patients 
who have undergone a near-total or total thyroidec-
tomy for well-differentiated thyroid cancer and who 
do not have evidence of distant metastases [35]. Rem-
nant ablation after preparation with rhTSH is associ-
ated with superior short-term quality of life, reduced 
whole-body irradiation and chromosomal abnormali-
ties and similar rates of successful remnant ablation 
as compared to traditional hypothyroidism. Although 
long-term outcome data following rhTSH preparation 
for RAI treatment are limited, the two studies published 
so far clearly show the same outcome of the patients 
independently from the type of stimulation. However, 
these studies are limited to low- and indeterminate-risk 
cases and randomized control trials are needed to guide 
clinical care in higher risk DTC patients.
A systematic reviews/meta-analyses of the studies show 
that similar rates of successful remnant ablation can be 
achieved using activities of 131I between 30 and 100 mCi 
in adult patients with well-differentiated thyroid carcinoma 
who had been treated with total or near-total thyroidectomy 
and who were not known to have any gross residual disease 
following surgery. No difference in terms of ablation suc-
cess rates was found in two prospective randomized studies 
conducted in France [36] and in the United Kingdom [37] 
using 30 or 100 mCi of 131I after preparation with thyroid 
hormone withdrawal or rhTSH. Regarding the impact of 
the low RAI activities for remnant ablation on long-term 
outcome, more controlled data from long-term studies are 
needed [38–40]. 
1. In preparation for remnant ablation, many centers rec-
ommend the use of a low-iodine diet (LID) to reduce the 
influence of the stable iodine on the uptake of therapeu-
tic activities of radioiodine. A recent systematic review 
of observational studies shows a reduction in urinary 
iodine excretion as well as an increase in 131I uptake in 
patients prepared with the most commonly studied LID 
when compared with patients not prepared with LID. 
On the other hand, a lack of association between urine 
iodine excretion and rate of successful thyroid ablation 
has been reported in patients not specifically prescribed 
an LID, suggesting that the routine measurement of uri-
nary iodine excretion may not be necessary. A retrospec-
tive study [41] shows no influence of different levels of 
urinary iodine on the outcome of thyroid ablation up to 
urinary iodine levels exceeding 350 µg/day of dietary 
iodine. In addition, occasionally, even patients on LID 
may show urinary iodine levels exceeding 500–1000 μg/
day. The use of iodized salt should not be restricted.
Item 11: Informing the patient treated 
with radioiodine on safety measures
References [42–44].
Recommendation statement
(a) Radioiodine treatment of thyroid cancer must be per-
formed in protected hospitalization with collection of 
patient excreta.
(b) At discharge, written information and instructions of 
behavior must be provided to the patient and his family 
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to respect the dose limits for the population and dose 
constraints for the family members or caregivers.
(c) Particularly, the written information at discharge must 
concern the patient travel after discharge, behavior in 
public and domestic environments, return to work, 
pregnancy and radiation–detection systems at interna-
tional borders, airports, and other public areas.
(d) Pregnancy is an absolute contraindications to 131I 
therapy. Pregnancy should be delayed for 6–12 months 
after radioiodine therapy; in men, conception should be 
avoided for 4 months after 131I therapy.
(e) Women who are lactating or have recently stopped 
breastfeeding should not be treated with 131I. Breast-
feeding must be stopped at least 6 weeks before admin-
istration of 131I therapy.
Narrative of the recommendation
The obligation of treatment in protected hospitalization 
with collection of patient excreta results by the Italian law 
187/2000, transposition of the European directive 97/43 
MED.
Witten instructions are provided to the patient and his 
family at discharge to respect the dose limits for the popu-
lation and dose constraints for the family members or car-
egivers. After radioiodine administration, the main source 
of radiation dose to family members, caregivers, and the 
general public comes from external exposure to high-energy 
gamma rays, according to three variables: the retained radi-
oiodine activity, the distance (inversely proportional to the 
square of the distance from the patient) and the duration of 
exposure (directly proportional to the time spent close to the 
patient). The second potential radiation exposure pathway of 
family members or caregivers is the contamination through 
131I excreted/secreted by the treated patient. The majority 
of the excretion of radioiodine occurs via the urine, maxi-
mal during the first 48 h after treatment. Small amounts of 
131I concentrations are present in the saliva for as long as 
7 days, stool, and other body fluids. Although contamination 
is much less important than external exposure as source of 
radiation dose, it is very important to pay attention to young 
children whose thyroid glands and other tissue are more sen-
sitive to radiation.
Pregnancy is an absolute contraindications to 131I 
therapy because of the consequent fetal irradiation and the 
possible transfer of radioiodine to the fetal thyroid. After 
radioiodine treatment, pregnancy should be delayed for at 
least 6 months.
During lactation, the mammary glands concentrate iodide 
at about 30 times the free inorganic plasma iodide concen-
trations via the increased expression of sodium iodide sym-
porter (NIS). Therefore, breastfeeding should be discontin-
ued to prevent 131I in the milk from reaching the infant’s 
thyroid gland and to limit the radiation absorbed dose to the 
mother’s breast tissue.
In young men, radioiodine therapy has been associated 
with a temporary reduction in sperm counts and transient 
elevated serum follicle-stimulating hormone (FSH) levels. 
However, for patients treated with a single ablation dose 
testicular function recovers within few months and the risk 
of infertility is almost absent. Permanent testicular damage 
may be observed after high cumulative doses of radioio-
dine. Sperm banking could be considered in young patients 
with distant metastases likely requiring high cumulative 
activities.
Sensitive radiation detectors installed in airports, pub-
lic transportation facilities, and other ports of entry can be 
triggered by patients who have received radioiodine. It is 
possible that patients treated with 131I could trigger alarms 
at such detection sites for 95 days or longer after treatment. 
If, after receiving 131I therapy, travel across international 
borders or via airports is planned, a form including the date 
of treatment, the radionuclide, the administered activity and 
the treating facility should be provided to the patient.
Item 12: Follow‑up after initial treatment 
(surgery and radioiodine): when and how
Recommendation statement
(a) The initial follow-up visit, aimed at defining the 
response to primary treatment, should be performed at 
6–12 months.
(b) In patients who have had total thyroidectomy with RAI 
remnant ablation or adjuvant therapy, the first-level 
tools for assessing responses to initial treatment should 
be: (a) serum Tg measurement on l-thyroxine therapy 
with a sensitive Tg assay or after TSH stimulation; (b) 
serum Tg antibodies measurement (not the recovery 
test); and (c) neck ultrasound.
(c) Functional (whole-body RAI scan, 18-fluoro-2-deox-
yglucose positron emission tomography scan) and/or 
cross-sectional (computed tomography, magnetic reso-
nance imaging) studies may be considered in patients 
with high risk of persistent disease, when response to 
therapy cannot be correctly classified with first-level 
tools.
(d) In patients with neck lesions sonographically suspi-
cious for malignancy, FNA cytology with Tg assay in 
the needle-washout fluid is recommended if this would 
change management.
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Narrative of the recommendation
The goals of the early post-operative follow-up are to 
tailor the TSH level to each patient’s risk of recurrence 
(2–3 months after initial treatment) and to identify patients 
who are disease-free and can be safely managed with less 
intensive surveillance, and those with persistent disease, 
who may require additional therapy or a more active sur-
veillance (6–12 months after initial treatment) [1]. Serum 
Tg assays and neck ultrasound are regarded as the first-level 
tools for assessing responses to initial treatment [2, 45, 46]. 
Functional and cross-sectional imaging studies play second-
line roles.
Undetectable serum ultrasensitive Tg levels (either basal 
or rhTSH-stimulated) and negative TgAb can reliably iden-
tify patients who are disease-free, with a negative predic-
tive value close to 100%. Minimally detectable Tg levels, 
especially after TSH stimulation, carry a very low positive 
predictive value. Indeed, most patients with incomplete or 
indeterminate response to therapy remain free of structural 
disease during prolonged follow-up. Reliable Tg cutoffs for 
distinguishing the meaning of detectable serum Tg have not 
been established. This reduces the specificity of positive 
Tg assay, especially when RAI remnant ablation is omit-
ted. Therefore, Tg trends rather than absolute levels should 
be monitored [47]. Declining levels are reassuring, whereas 
rising values suggest the presence of growing thyroid tissue 
or cancer. However, on this regard, it is worth to note that to 
compare Tg values, the measurement should be done pos-
sibly in the same laboratory and with the same assay. The 
TSH values must also be considered, since small variations 
of TSH can greatly affect the serum Tg values. Immuno-
metrically determined Tg levels can be falsely lowered by 
the presence of Tg autoantibodies which must always be 
measured simultaneously to Tg. Temporal trends in the anti-
body titers can help to distinguish residual normal thyroid 
tissue from recurrent tumor, although they are less reliable 
than serum Tg trends.
Cervical ultrasound provides prompt information during 
follow-up, including the initial phase when Tg assay results 
may be difficult to interpret. Thyroid cancer spread or recur-
rence usually begins in the cervical lymph nodes, where it 
can be sonographically identified using well-established cri-
teria. Ultrasound-guided FNA and FNA-Tg can be used to 
confirm suspicious findings thereby increasing specificity 
(see “Item 3”). In patients at high risk of persistent disease, 
or in the presence of negative findings on neck US associ-
ated with elevated serum Tg levels or rising serum Tg or Tg 
antibody levels, second-line imaging studies should be used 
to exclude the presence of metastatic lesions.
Item 13: Risk stratification incorporating 
the response to initial treatment
Recommendation
(a) The ATA Initial Risk Stratification System (low–inter-
mediate–high risks) is recommended for DTC patients 
treated with thyroidectomy.
(b) At 6–12 months, the initial recurrence risk estimates 
should be modified to incorporate the response to initial 
therapy.
(c) Risk estimates should be further modified during fol-
low-up, as a function of the clinical course of the dis-
ease.
Narrative of the recommendation
Initial risk stratification provides important information into 
an individual patient’s risk of recurrence and disease-specific 
mortality and can dictate the need for radioiodine therapy. 
However, they are derived only from personal and pathologi-
cal features available at the time of initial therapy, and thus, 
they do not take into account the response to initial therapy 
or to new features discovered during follow-up. By incorpo-
rating this additional information, we can get a dynamic risk 
stratification which can change over time according to the 
clinical course of the disease. An ATA low-risk patient that 
develops cervical lymphadenopathy at some point during 
follow-up would be reclassified as intermediate or high risk. 
Conversely, an ATA high-risk patient that has no evidence 
of disease during follow-up would be reclassified as low 
risk. Dynamic risk stratification avoids aggressive treatment 
for patients that after initial therapy become free of disease 
(low risk) regardless of the initial risk attributed based on 
personal data and histopathology.
Response to initial therapy includes the following 
categories:
1. Excellent response: negative or non-specific structural 
or functional imaging findings and either suppressed 
Tg < 0.2 ng/mL or TSH-stimulated Tg < 1 ng/mL;
2. Biochemical incomplete response: negative imaging and 
detectable basal or stimulated Tg or rising anti-Tg anti-
body levels;
3. Structural incomplete response: evidence of disease at 
structural or functional imaging, with any Tg level, with 
or without anti-Tg antibodies.
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Item 14: Follow‑up of patients with excellent 
response to initial therapy
Recommendation statement
(a) In DTC patients with an excellent response to ini-
tial treatment, follow-up should be performed every 
12–24 months.
(b) In patients who achieve an excellent response to ther-
apy, irrespective of initial treatment, follow-up should 
be based on measurement of basal Tg levels (with ultra-
sensitive assays < 0.2 ng/mL) under l-thyroxine, anti 
thyroglobulin antibodies and neck ultrasound.
(c) In these patients,  l-thyroxine therapy should 
aim to keep TSH levels in the low–normal range 
(0.5–2 mUI/L).
Narrative of the recommendation
Patients’ follow-up should be performed every 
12–24 months. After 5 years, the frequency of follow-up 
visit may be lengthened. As tumor recurrence can happen 
also several years after surgery/radio remnant ablation, fol-
low-up should be continued lifelong [48].
In patients who underwent total thyroidectomy (without 
RAI), there are not specific cutoff to assess the absence of 
tumor persistence/relapse because of the possible presence 
of the normal thyroidal tissue. Monitoring Tg levels to assess 
the Tg trend, together with neck US, is suggested to dis-
tinguish between residual normal thyroid tissue and tumor 
relapse [47].
In patients who underwent successful RAI remnant abla-
tion after surgery, undetectable ultrasensitive serum Tg lev-
els (< 0.2 ng/mL) on LT4 are highly predictive of tumor 
absence. Rising Tg values overtime are highly predictive of 
recurrent disease [49].
In addition, as most of DTC recurrences occur in the neck 
(in thyroid bed or in cervical lymph nodes), combining neck 
US to Tg assessment is the most accurate follow-up strategy 
for these patients [50]. Neck US can detect structural tumor 
relapse also in the absence of Tg elevation. In case of suspi-
cious neck lesions, US guided FNA should be considered, 
with Tg assay on needle-washout fluid.
In case of undetectable Tg on LT4 and in the absence 
of suspicious findings, further Tg measurement after TSH 
stimulation is not routinely recommended.
Item 15: Follow‑up of patients 
with persistent structural disease 
or biochemical disease
Recommendation statement
Persistent biochemical disease
(a) Patients with persistent biochemical disease should 
undergo periodic Tg and TgAb measurements and 
neck ultrasound on l-T4 treatment, approximately every 
6–12 months.
(b) A progressive increase of Tg level with a doubling time 
period lower than 12 months indicates a rapid progres-
sion and requires additional morphological examina-
tions to assess the presence of structural disease.
(c) TSH-stimulated Tg testing may be helpful only for 
re-staging patients, after additional therapies. In 
these patients, we recommend a moderate (TSH 0.1–
0.5 mIU/mL) or complete (TSH < 0.1 mIU/mL) TSH 
suppression that should be individualized according to 
Tg or TgAb values and their trend of increase.
Persistent structural disease
(a) Patients with persistent structural disease need an active 
surveillance and should undergo periodic morphologi-
cal examinations to assess the status of disease and to 
evaluate the need and the appropriateness of treatment.
(b) An individualized follow-up program should be 
planned according to site and burden of metastases, 
131I uptake, and avidity and FDG-PET uptake.
(c) The level of TSH suppression should be < 0.1 mU/l.
Narrative of the recommendation
Persistent Biochemical disease (for definition, see chap-
ter 13). Persistent biochemical disease is observed in about 
10–20% of DTC and in all risk categories. According to 
Tg values, this condition is defined as “incomplete bio-
chemical response” (Tg on LT4 > 1 ng/mL and TSH-stim-
ulated > 10 ng/mL) and is different from an “indeterminate 
response” (with Tg on LT4 < 1 ng/mL and TSH-stimu-
lated < 10 ng/mL) frequently characterized by concomitant 
non-specific imaging findings. In some patients, persistently 
high or rising TgAb levels, in the absence of detectable Tg, 
indicate persistent disease. Outcome: during follow-up, 
about 20% of patients with persistent biochemical disease 
will progress with appearance of structural disease [51, 52]. 
Remaining patients will not have evidence of progression 
during the long-term follow-up, often without any additional 
treatment. Death rate is < 1%.
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Persistent Structural Disease (see chapter 13): Persistent 
structural disease is observed in all DTC risk categories with 
highest prevalence in high-risk tumors. The most common 
sites of loco-regional disease are cervical lymph nodes. Dis-
tant metastases are more frequent in lung followed by bone.
131I treatment is useful in case of iodine avidity. In 
patients with persistent disease after a cumulative activity 
of more than 600 mCi, an alternative therapy should be con-
sidered [53] if the disease is progressing. RAI refractory 
tumor has a high probability of progression and will require 
systemic therapy with TKI during follow-up. FDG-PET is 
useful for prognostic purpose and when tumor lesions are 
FDG-PET positive prognosis if unfavorable [54].
Whenever systemic treatment is advocated, the decision 
should not be taken according to strict RECIST criteria. 
These should be limited to experimental clinical trials.
Tumors with low tumor burden, and also small metastatic 
lymph nodes should be followed without additional therapy. 
Localized or single metastases may require an individual-
ized treatment, with surgery or external beam radiotherapy 
or other therapeutic options as embolization or radiofre-
quency. About 50–80% of these patients will have persis-
tent disease during the long-term follow-up despite medical 
treatment with a specific mortality of 11% in patients with 
loco-regional disease and in almost 60% in patients with 
distant metastases.
Item 16: Follow‑up of patients treated 
with lobo‑isthmectomy
Recommendation statement
(a) Following lobo-isthmectomy, cervical US to evaluate 
the thyroid bed and central and lateral cervical nodal 
compartments should be performed at 3–6 months and 
then periodically, according to the patient’s risk for 
recurrent disease and Tg levels which should be evalu-
ated on thyroid hormone therapy.
(b) In patients treated with lobo-isthmectomy, response to 
treatment should be evaluated, as follows:
Excellent response: stable non-stimulated Tg levels, 
consistent with the presence of a normal thyroid lobe, 
negative US.
Biochemical incomplete response: elevated non-stim-
ulated Tg levels not consistent with the presence of 
a normal thyroid lobe or serum Tg levels increasing 
over time in the presence of similar TSH levels, nega-
tive US.
Structural incomplete response: structural evidence of 
disease, regardless of serum Tg.
Indeterminate response: non-specific findings on US 
and/or Tg trend not assessable.
(c) Diagnostic and therapeutic actions should be based on 
the response to initial therapy, as follows:
Excellent response: decrease in the intensity and fre-
quency of follow-up;
Biochemical incomplete response: additional imaging 
and potentially additional therapies;
Structural incomplete response: completion thyroid-
ectomy or ongoing observation according to multiple 
clinico-pathologic factors including age, size, location, 
rate of growth, and 18FDG avidity;
Indeterminate response: continued observation with 
appropriate serial imaging of the non-specific lesions 
and serum Tg monitoring.
Narrative of the recommendation
These recommendations apply to patients submitted to lobo-
isthmectomy. Since the majority of recurrences will occur 
either in the contralateral lobe or in cervical lymph node 
metastases, neck ultrasonography remains the key modality 
to identify disease recurrence. The follow-up with radioac-
tive iodine scanning is not helpful and serum thyroglobulin 
values are thought to have less value than in patients treated 
with total thyroidectomy and RAI ablation.
In 2013, Vaisman et al. [55] reported a structural recur-
rence rate of 7.1% in a cohort of 70 low–intermediate-risk 
patients followed for a median of 11 years with thyroglob-
ulin values and serial neck ultrasound examinations after 
thyroid lobectomy for papillary thyroid cancer. Importantly, 
99% of the patients were subsequently rendered free of dis-
ease after identification and treatment (by surgery and/or 
RAI) of their recurrent disease. The primary modality for 
detection of structural disease recurrence was neck ultra-
sound, while a trend in serum Tg over time that was stable 
or declining made it very unlikely that disease recurrence 
would be identified.
Specific cut-off levels of Tg to distinguish normal residual 
thyroid tissue from persistent thyroid cancer are unknown. 
Nevertheless, in 2016, Momesso et al. [56] demonstrated 
that stable, non-stimulated levels < 30 ng/mL, and unde-
tectable TgAb with negative imaging are suggestive for an 
excellent response after initial treatment. On the other hand, 
regardless of the cutoff, rising non-stimulated Tg are the 
strongest predictor of recurrent/persistent structurally evi-
dent disease.
The presence/absence and/or the trend of TgAb levels 
cannot be considered in the follow-up of patients submitted 
to lobectomy, due to the presence of the residual lobe.
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Item 17: Is there an indication for rhTSH 
in the preparation of patients undergoing 
radioiodine therapy for metastatic disease?
Recommendation statement
(a) The use of rhTSH is not routinely recommended for 
radioiodine therapy of loco-regional and distant metas-
tases from DTC because has not been registered for this 
use.
(b) Recombinant human TSH–mediated therapy can be 
used according the the Italian law (648/96).
• Patients whose serum TSH cannot be raised (at least 
30 µUI/mL) because of primary or secondary pitui-
tary disease or functional metastasis.
• Patients with underlying comorbidities making iat-
rogenic hypothyroidism potentially risky:
• previous cerebral stroke or TIA;
• cardiomyopathy (NYHA grade III or IV);
• severe renal failure (stage 3 or superior);
• serious mental disorders (severe depression, psycho-
sis).
(c) Such patients should be given higher activity that would 
have been given had they been prepared with hypothy-
roidism or a dosimetrically determined activity.
Narrative of the recommendation
Although rhTSH has been used “off-label” safely and some-
times with efficacy in hundreds of patients with metastases 
from DTC, since the drug has not undergone a prospective 
Phase 3 study for this indication, it has not been registered 
for this use. In addition, only limited data have been pub-
lished on radioiodine kinetics in metastatic tissue under 
rhTSH stimulation and publications to date comprise only 
case reports or small non-prospective and non-randomized 
studies. Currently, there are insufficient outcome data to 
recommend rhTSH-mediated therapy for all patients with 
distant metastatic disease being treated with 131I.
The few published experience usually showed that rhTSH 
can stimulate the uptake of radioiodine in metastatic lesions, 
but suggested that stimulation by rhTSH may be less effec-
tive than hormone withdrawal in concentrating radioiodine 
into metastatic lesions. This can be due to several reasons.
• First, the TSH elevation achieved with rhTSH is sharper, 
but much shorter lived than that attained by THW. More 
protracted TSH stimulation (as obtained by THW) might 
result in enhanced DTC cell expression or trafficking of 
NIS, which might lead to higher radioiodine uptake.
• Second, normal residual thyroid tissue and metastatic tis-
sue are biologically distinct. Neoplastic tissue has much 
less ability to concentrate iodine and may require more 
profound TSH stimulation, obtained more through THW 
than by means of rhTSH administration. However, no 
comparative data are available on this specific issue.
• Finally, the markedly faster (by ~ 50%) renal excretion of 
radioiodine under euthyroid conditions (rhTSH admin-
istration) compared to hypothyroid conditions (THW) 
raises the possibility that the radiation absorbed dose (Gy 
delivered to the lesions) by a given 131I activity could 
differ appreciably between the two TSH stimulation 
methods. Freudenberg et al. [57] reported a delivered 
lower radiation doses per GBq of administered activ-
ity after rhTSH than after THW in distant metastases. 
Similar results have been reported in a small pilot study 
by Pötzi et al. [58] using lesion cumulative activity in 
μCi as a surrogate marker for lesion dose. Though visual 
analysis of the rhTSH post-therapy scans showed con-
centration of 131I in most metastatic sites, Rani et al. [59] 
recently reported that the mean effective half-life of 131I, 
the mean 24-h  % uptake and the mean tumor radiation 
absorbed dose per administered MBq (mCi) in lung or 
skeletal metastases was less during the rhTSH protocol 
than THW protocol. Despite these evidences, the results 
obtained by Tala et al. [60] in two groups of metastatic 
patients treated with 131-I and prepared with rhTSH or 
TWH were similar, but the study has several limitations 
including a four injection regimen of rhTSH administra-
tion.
These controversial and inaccurate data are the main rea-
sons for which rhTSH cannot be recommended yet for the 
preparation of radioiodine treatment in patients with known, 
or at high risk of having, neoplastic foci, except those who 
cannot tolerate withdrawal for underlying comorbidities 
(e.g., previous cerebral stroke or TIA, cardiomyopathy, strict 
renal failure or serious mental disorders) or patients whose 
serum TSH cannot be raised because of primary or second-
ary pituitary disease or functioning metastases. In Italy, 
the Italian Medicines Agency (AIFA) approved this use in 
patients with metastatic disease, defining the new indications 
and the additional criteria for reimbursement of rhTSH on 
the basis of law 648/96.
Because significant morbidity from swelling of metastatic 
tissue following rhTSH administration has been described, 
rhTSH needs to be used cautiously in patients with metas-
tases in “closed spaces” in the body, such as brain or spine. 
The institution of temporary high-dose corticosteroid ther-
apy is recommended for trying to limit the risk of acute 
tumor swelling, probably depending on a higher vasculari-
zation of the lesion with increasing of the edema than a real 
tumor mass growing.
866 Journal of Endocrinological Investigation (2018) 41:849–876
1 3
A large, well-controlled, prospective, within patient study 
is needed to resolve the clinically important item of whether 
lesion doses significantly differ between the two TSH stimu-
lation methods. Until data from such a study become avail-
able, we suggest reserving rhTSH-aided treatment of meta-
static DTC to patients who are unable to tolerate THW or to 
increase TSH levels by TSH endogenous stimulation.
Item 18: Radioiodine treatment 
of metastatic disease: standard doses vs. 
dosimetry, maximal cumulative activity, 
frequency of treatment courses
Recommendation statement
(a) The selection of radioiodine activity to administer in 
the treatment of loco-regional or distant metastases 
from DTC can be determined empirically (fixed or 
empiric activities ranging from 3.7 to 7.4 GBq, 100–
200 mCi) or by dosimetry.
(b) Empiric activities ranging between 3.7 and 7.4 GBq 
(100–200 mCi) appears to be a reasonable option for 
most patients. Amounts of 131I exceeding 7.4 GBq 
(200 mCi) are not recommended in elderly patients 
(> 70  years) and patients with renal insufficiency 
because the maximum tolerated radiation absorbed 
dose (2 Gy to the blood) is potentially exceeded.
  In these patients, dosimetry could be considered.
(c) The total number of treatments that can be performed 
in the same patient and the time occurring between two 
treatments cannot be established in a strict way. The 
decision must be individualized and based on several 
factors, including the disease response to treatment 
(e.g., decreasing of the size/number of the lesions and/
or serum Tg levels), the age of the patient and the onset 
of deterministic effects (e.g., radiation lung damage, 
bone-marrow suppression and salivary gland damage). 
However, retreatment should be preferably performed 
not earlier than 6–12 months from previous treatment.
Narrative of the recommendation
Although there are theoretical advantages to prefer dosim-
etry, to date, outcome data are insufficient and no recom-
mendation can be made about the superiority of dosimetry 
over fixed activities. Dosimetry plays an important role in 
selected cases (e.g., patients with or extensive pulmonary 
metastases, elderly patients or patients with unusual situ-
ations such as renal insufficiency) and it is exceptionally 
helpful in clinical trials.
Three basic approaches have been described to select the 
activity of radioiodine for treatment of metastatic disease.
Fixed or empiric activities
All patients with a given clinical situation (e.g., lymph node, 
lung or bone metastases) get the same radioiodine activ-
ity [e.g., 3.7 GBq (100 mCi)–7.4 GBq (200 mCi)]. This is 
the easiest and common approach used in clinical practice, 
with a long history of use, a high grade of convenience and 
a reasonably acceptable rate and severity of complications. 
However, given the heterogeneity of patients with metastatic 
disease, this is clearly the most arbitrary method of select-
ing therapy that has the potential to under treat some patient 
while over treating others.
Bone‑marrow (blood) dosimetry
The second approach is to use quantitative methods to deter-
mine the maximum tolerated activity (MTA) of radioiodine 
that could be administered within a safe upper limit of 
absorbed dose to non-target tissues, such as the bone mar-
row or lungs in the presence of diffuse metastases. With this 
technique, the 131I activity is calculated to deliver a maxi-
mum of 2 Gy to the whole blood to avoid serious myelo-
suppression. In addition, the whole-body retention at 48 h 
after radioiodine administration should not exceed 4.4 GBq 
(120 mCi) in the absence of iodine-avid diffuse lung metas-
tases or 2.96 GBq (80 mCi) in the presence of such lesions. 
The theoretical rationale for administration of the MTA is 
based on the concept that a maximal safe prescribed activity 
should have greater therapeutic benefit than multiple smaller 
empiric activities that may induce nonlethal changes in the 
cancer tissue with subsequent cellular repair. However, the 
approach does not estimate the absorbed radiation dose to 
the metastasis and the MTA may be given without any thera-
peutic effect.
Lesion‑based dosimetry
The objective of this method is to determine the radioiodine 
activity that delivers the recommended absorbed radiation 
dose to the metastases whilst minimizing the risk to the 
patient. The traditionally recommended radiation absorbed 
dose to successfully treat metastatic disease is 80–120 Gy 
(80% control rate) [61]. The strength of this approach is a 
more selective exposure to individual patients based upon 
their individual needs without an increase in radiation 
exposure to the patient population. However, several disad-
vantages of the quantitative tumor dosimetry are reported 
including the incomplete tumor destruction due to the wide 
range of absorbed lesion doses within a single patient and 
within different lesions, the impossibility to accurately esti-
mate the lesion mass in case of disseminated metastases or 
irregularly shaped lesions, the systematic absorbed doses 
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underestimation for lesions < 5 mm in diameter and/or with 
low radioiodine uptake.
In the only retrospective comparison between fixed activ-
ity and dosimetry, no difference in the patient’s outcome 
has been found [62]. In general, patient-specific dosimetry 
requires a number of scintigraphic scans and staff resources. 
Several factors can limit the implementation of patient-spe-
cific dosimetry, such as shortage of knowledge and know-
how, shortage of medical physicists working in nuclear 
medicine, limited access to scanner and dedicated software.
In case that dosimetry is preferred, the administered 
activity calculated on the lesions should be lowered if the 
MTA to the blood is inferior to that activity.
Item 19: “Empiric” treatment 
with radioiodine in Tg positive/diagnostic 
WBS negative patients: still an indication?
Recommendation statement
(a) Empiric treatment with RAI (100–150  mCi, 3.7–
5.2 mBq) may be considered in patients with elevated 
serum Tg levels or rapidly rising serum Tg levels or 
rising anti-Tg antibody levels and negative macroscopic 
structural (US, TC, RMI) or metabolic (FDG-PET/CT) 
imaging.
(b) If the post-therapy scan is negative and structural dis-
ease is evident, further RAI therapy should never be 
used and the patient should be classified as RAI refrac-
tory.
(c) On the contrary, if the post-therapy scan shows the 
presence of metastatic disease significantly taking up 
radioiodine, further treatment courses can be consid-
ered as long as evidence of clinical benefit is provided.
Narrative of the recommendations
After a period of great enthusiasm in favor of empiric 
treatment with RAI in Tg positive/scan negative patients 
[63], recent data have indicated that the benefit from such 
therapy are almost negligible [64]. Thus, the indication for 
empiric RAI therapy has been dramatically limited to very 
selected patients. In addition, one has to keep in mind that 
this empiric approach does not fulfill the first principle of 
radiological exposure according to which any radiological 
procedure or therapy must be “justified”. Furthermore, no 
target dosimetry is possible under these circumstances. 124I 
PET/TC could offer more information in these patients.
The objective of empiric RAI therapy is mainly to aid in 
disease localization, and, hopefully shrinkage of the tumor. 
The first aim is achieved in one-third of patients. Therapeu-
tic benefits are reported in a minority of patients either as a 
decline in serum Tg or stabilization of tumor size, particu-
larly in case of micro-metastases in the lung. However, there 
is no evidence for improved survival.
Two main factors should be considered for decision 
making: the level of serum Tg elevation and the results of 
18FDG-PET. As far as the Tg levels are concerned, there is 
no consensus of the serum Tg cutoff above which an empiric 
dose of RAI should be delivered. In addition, evidence is 
provided that slightly elevated stimulated serum Tg (< 10 ng/
mL) may decrease spontaneously, without any therapy, dur-
ing follow-up. A good compromise is to use cut-off levels 
of serum Tg above which a spontaneous decline is unlikely 
to occur, particularly when these serum Tg levels or TgAb 
levels are rising over time.
Metastatic lesions that are 18FDG-PET positive gener-
ally do not concentrate RAI. In this setting, RAI therapy 
is unlikely to be beneficial and because of this, it is recom-
mended that empiric RAI therapy should be administered 
mainly in patients with negative 18FDG-PET.
Item 20: Adverse events of radioiodine 
therapy
Recommendation statement
(a) Nausea, taste disturbance and salivary gland swell-
ing are the most common early side effects. Recom-
mended measures to prevent damage to the salivary 
glands include hydration and sour candies or lemon 
juice administration.
(b) Women of childbearing age should avoid pregnancy for 
6–12 months after receiving radioiodine.
(c) Depending on the clinical situation, radioiodine therapy 
could be deferred until lactating women have stopped 
breastfeeding or pumping for at least 3 months.
(d) Men receiving cumulative radioiodine activi-
ties ≥ 400 mCi should be counseled on potential risks 
of infertility.
(e) Although present, the risk of developing a second pri-
mary malignancy (SPMs) due to radioiodine therapy 
in long-term survivors is considered very small and 
related to the cumulative activity. There is no evidence 
of increased risk of SPMs after a single administration 
of radioiodine for ablative treatment.
Narrative of the recommendation
Radioiodine therapy is generally well-tolerated, and in most 
cases, the early deterministic effects are of scarce clinical 
relevance. However, both the choice of the single and cumu-
lative activities and the patient’s preparation (e.g., using lax-
atives, oral hydration, diuretics or a short course of steroids) 
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should be accurate to minimize the risk of early and late 
side effects.
The main deterministic effects of radioiodine therapy in 
patients with DTC can concern the salivary glands (taste 
disturbance, swelling, sialoadenitis, xerostomia, salivary 
duct obstruction), eye and nasolacrimal gland (xerophthal-
mia, epiphora, conjunctivitis), genital system (hypospermia 
and azoospermia in males and temporary amenorrhea or oli-
gomenorrhea in females), lungs (very rare acute radiation 
pneumonitis and fibrosis) and bone marrow (neutropenia, 
low platelet count and anemia) [65]. Most of these effects are 
early and transient, but some of them may become perma-
nent and appear only months or years after treatment, such 
as bone-marrow depression, radiation pulmonary fibrosis, 
early onset of menopausa in women, oligospermia in men 
and chronic dry eye.
Objective salivary gland dysfunction [66] (abnormal 
scintigraphic findings, defined as decreased salivary secre-
tion and excretion fraction) are significantly more frequent 
observed after I-131 therapy when compared intra-individ-
ually (before I-131) and when compared to controls with-
out exposure to I-131. The prevalence of objective salivary 
dysfunction after I-131 ranged from 37 to 72%. The admin-
istered cumulative I-131 activity in relation to objective 
salivary gland dysfunction is an important risk factor. The 
prevalence of symptomatic salivary gland dysfunction is 
lower than objective salivary gland dysfunction (16–54 vs. 
37– 72%, respectively) indicating that objective salivary dys-
function may be present in the absence of symptoms. Symp-
tomatic salivary gland dysfunction correlated well with the 
cumulative I-131 activity.
Objective lacrimal gland dysfunction is defined as an 
abnormal functional tear test (Schirmer’s tear test, tear film 
break-up time, etc.). An abnormal Schirmer’s tear test is 
found significantly more frequently in patients exposed to 
I-131 compared to unexposed patients.
Regarding male gonadal dysfunction [67] the prevalence 
of oligospermia after exposure to I-131 ranges from 25 to 
50%. Follicle-stimulating hormone (FSH) concentrations are 
significantly increased (from 35 to 100% in respect to nor-
mal range) after I-131 therapy compared to the values meas-
ured before exposure to I-131, with a maximal FSH increase 
6 months after I-131 therapy. On average, mean concen-
trations of serum FSH has normalized 18 months after the 
last I-131 treatment. However, for patients treated with high 
activities of I-131, the risk to develop persistent elevated 
serum FSH concentrations is increased. Mean serum lutein-
izing hormone (LH) concentrations are transiently increased 
after I-131 therapy. Serum testosterone concentrations are 
not significantly changed.
Female gonadal function evaluation reveals temporary 
amenorrhea and menstrual irregularities in 20–27% of 
patients [68]. In one study, a significant younger menopausal 
age in DTC patients who received I-131 compared to sub-
jects who did not receive I-131 therapy is observed (49.5 
vs. 51.0 years). Most studies have demonstrated that the 
birthrate in female patients is not affected by the treatment 
with I-131. The reduced birthrate reported by other studies 
may be explained by a possible impact of I-131 therapy on 
both reproductive choice and health. In one study, it has 
been observed that the overall median time to first deliv-
ery following initial presentation of DTC is significantly 
longer in women who received I-131 therapy compared to 
patients who did not (34.5 vs. 26.1 months). In addition in 
this case, it could not be excluded that this delay may have 
been influenced by physicians’ recommendations to avoid 
pregnancy for 6–12 months after I-131 therapy or may have 
been related to hormonal imbalances caused by hypothyroid 
state. I-131 therapy is not a risk factor to bear a miscar-
riage or preterm birth deliveries in pregnancies occurring 
after I-131 administration. In one study, however, signifi-
cantly more preterm deliveries were found in patients who 
received I-131 therapy compared to patients who did not 
(9.1 vs. 1.4%). No increased incidence of congenital abnor-
malities in the offspring of women previously treated with 
I-131 is found.
The possible induction of second primary malignan-
cies (SPMs) is one of the most relevant untoward effects 
of radioiodine treatment particularly when the cumulative 
activity was > 37 GBq (> 100 mCi) [69]. A meta-analysis of 
two large multicenter studies showed that the relative risk 
(RR) of SPMs after radioiodine therapy (relative to thyroid 
cancer survivors not treated with radioiodine) was signifi-
cantly increased for solid tumors and leukemia at 1.19 ([95% 
CI 1.04–1.36], p < 0.010) and 2.5 ([95% CI 1.13–5.53], 
p < 0.024), respectively. However, in all studies the absolute 
increase in second primary malignancy risk attributable to 
radioiodine is considered to be very small. These studies 
showed an increased risk linked to increasing doses of radi-
oiodine for salivary glands, digestive tract and soft-tissue 
and bone sarcomas. A study on patients with low-risk DTC 
(T1N0 PTC) from the SEER registry concluded that the 
excess risk of leukemia after radioiodine therapy was sig-
nificantly greater (standardized incidence rate of 5.32 [95% 
CI 2.75–9.30] in young individuals (aged < 45) compared 
with older individuals (standardized incidence rate of 2.26 
[95% CI 1.43–3.39]
Item 21: Definition of RAI refractory disease
Recommendation statement
(a) A thyroid cancer can be defined as RAI refractory when 
at least one of the following patterns is verified:
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• Evidence of measureable metastatic lesion(s) not 
able to take up radioiodine, as demonstrated by a 
negative post-therapeutic 131-I whole-body scan.
• Evidence of measureable metastatic lesion(s) not 
able to take up radioiodine, as demonstrated by a 
negative 131-I whole-body scan, even if accompa-
nied by other lesions still able to take up iodine.
• Evidence of measureable metastatic lesion(s) that, 
despite their ability to take up iodine, are growing 
between one 131-I treatment and the following, thus 
indicating the ineffectiveness of 131-I therapy.
Narrative of the recommendation
Differentiated thyroid cancer (DTC) is considered as a tumor 
with an excellent prognosis, with a 93–95% survival rate. 
The initial therapy, in particular for intermediate and high-
risk patients, is total thyroidectomy (TTx) plus/minus radi-
oiodine remnant ablation (RRA). In the majority of cases, 
this initial therapy is sufficient to cure the patients. About 
5% of patients with DTC show distant metastases at the time 
of the diagnosis. 131-I therapy is the therapy of choice and 
treatments should be repeated until the evidence of 131-I 
uptake. About 30% of these patients will be cured with this 
therapy while the other sooner or later will become RAI 
refractory and will require other therapies. The overall sur-
vival of this group of patients may be significantly lower 
when compared with other groups that retain the ability to 
take up radioiodine.
There are evidences that the mean cumulative activity 
of 131-I within which we can expect to cure the metastatic 
DTC patient is 22 GBq (600 mCi). For this reason, sev-
eral authors suggest that after this total activity is reached 
the 131-I treatments must be stopped and the tumor can be 
considered RAI resistant or refractory. Although every-
body agrees that patients who are not cured before reach-
ing this cumulative activity of 131-I will likely never cured 
by 131-I, several experts are convinced that those patients 
who showed a “stable disease” (i.e., same size and same 
number of lesions) under 131-I repeated treatments (every 
12–18 months) should not be considered as RAI resistant or 
refractory. These patients should be continued to be treated 
with 131-I until the evidence of clinical benefit, and the sta-
bility of the disease can be considered a clinical benefit, par-
ticularly if the patient is in good general health conditions.
In patients with metastatic DTC, it is not rare to observe 
the heterogeneous behavior of RAI uptake in different meta-
static lesions. This pattern is rather typical in patients with 
large and multiple metastases as demonstrated in studies 
with 124I-PET-CT scan [70]. In these cases is rather fre-
quent to observe the “flip-flop” phenomenon that describes 
the situation of simultaneous metastatic lesions that are 
either 18FDG-PET negative but 131-I WBS positive or 
18FDGPET positive but 131-I WBS negative. Moreover, it 
has been well demonstrated that the 18FDG PET positivity 
is “per se” a poor prognostic factor for survival independent 
from the ability of the metastatic lesions to take up iodine 
[54]. On the basis of these observations, 18 FDG-PET posi-
tive metastatic lesions can be considered as RAI resistant 
or refractory.
Item 22: What is the role of systemic 
therapy (kinase inhibitors, conventional 
chemotherapy) in treating metastatic DTC?”
Recommendation statement
(a) Before selecting systemic therapies, a rigorous screen-
ing should be performed to assess whether one or more 
lesions are candidate to local therapies.
(b) Patients with locally advanced and/or metastatic RAI 
refractory disease, rapidly progressive, significantly 
symptomatic and/or with life threatening lesions not 
suitable for local therapies should be considered for 
systemic treatment.
(c) The major roles of systemic therapy is to reduce the 
growth rate and/or to reduce the tumor burden to 
improve the progression free survival of patients and, 
possibly, to control the symptoms related to the neo-
plastic disease.
(d) Nowadays, multikinase inhibitors approved by FDA and 
EMA (i.e., sorafenib and lenvatinib) are considered as 
the first line systemic therapy for advanced, RAI refrac-
tory and progressive DTC.
(e) Traditional chemotherapy is no more indicated with the 
exception of cases in whom the TKI are ineffective or 
cannot be used.
(f) Patients with stable RAI refractory metastatic disease 
without any symptoms, with a slow progression during 
the follow-up and without metastatic lesions at risk of 
life may be monitored with active surveillance at regu-
lar intervals (3–12 months) by cross-sectional imaging 
under TSH suppressive thyroid hormone therapy.
Narrative of the recommendation
Systemic therapy should be initiated when the progression of 
the local or metastatic disease is documented with radiologi-
cal imaging and according to Response Evaluation Criteria 
in Solid Tumors (RECIST). In some cases (i.e., large tumor 
burden, high risk of compression or infiltration of neighbor-
ing organs), the systemic therapy can be initiated even in the 
absence of a proved progression.
However, whenever the progression of the disease or its 
riskiness is related to a single lesion treatable with a local 
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treatment selective therapies (i.e., thermoablation, external 
radiotherapy, ethanol injection, chemoembolization, local 
surgical treatment etc.) are better indicated and strongly 
suggested
At present, tyrosine kinase inhibitors (TKI) represent the 
first choice systemic therapy since chemotherapy, both as 
single agent or in combination, has never given a durable 
clinical benefit. Two drugs are nowadays available, sorafenib 
[71] and lenvatinib [72], which have been demonstrated 
to significantly improve the progression free survival of 
patients treated with the drug with respect to those treated 
with placebo. Moreover, both studies showed also a sig-
nificant increase of the objective response rate in patients 
treated with the drugs with respect to patients treated with 
placebo. However, it should be noted that a prolongation of 
survival has never been demonstrated in clinical trials. This 
does not mean that there is no survival benefit, due to the 
bias of the possibility for the patients in the placebo group 
to shift to TKI when the blind has been open.in clinical trials
When disease progression is demonstrated during TKI 
therapy, the shift to another TKI is indicated based on 
evidence that the second drug has high chance of being 
effective.
Since TKI are cytostatic but not cytotoxic drugs, they 
should be started when the disease is progressing. How-
ever, since they are also potent antiangiogenic drugs, a rapid 
devascularization and consequent shrinkage of tumor lesions 
is expected. This latter activity can have also a significant 
impact on symptoms due to the pressure or infiltration of 
other organs.
Item 23:  l‑Thyroxine therapy after total 
thyroidectomy or lobo‑isthmectomy
Recommendation statement
Degree of TSH suppression after initial treatment
The degree of initial TSH suppression depends on the risk 
classification after initial treatment. Age and comorbidities 
should also be considered.
(a) ATA high-risk thyroid cancer patients: initial TSH 
suppression to ≤ 0.1 mU/L, unless contraindicated by 
concurrent diseases;
(b) ATA intermediate-risk thyroid cancer patients: initial 
TSH suppression to 0.1–0.5 mU/L;
(c) ATA low-risk patients who have undergone or not rem-
nant ablation and have undetectable serum Tg levels: 
TSH in the normal range (0.5–2 mU/L);
(d) ATA low-risk patients who have undergone remnant 
ablation and have low serum Tg levels: TSH may be 
maintained at or slightly below the lower limit of nor-
mal (0.1–0.5 mU/L);
(e) ATA low-risk patients who have undergone lobectomy: 
TSH may be maintained in the mid to lower reference 
range (0.5–2 mU/L).
Note: In patients treated by lobectomy and living in an 
iodine deficient country,  l-thyroxine treatment may be con-
sidered to reduce the TSH-induced thyroid nodular hyper-
plasia of the residual lobe, considering, age, TSH levels and 
ultrasound feature of the remaining lobe.
Degree of TSH suppression during follow‑up [1]
The degree of TSH suppression depends on the ongoing 
risk classification. Age and comorbidities should also be 
considered.
(a) Patients with a structural incomplete response to ther-
apy, regardless of the initial ATA risk classification: 
TSH should be maintained ≤ 0.1 mU/L, in the absence 
of specific contraindications.
(b) Patients with a biochemical incomplete or indetermi-
nate response to therapy, regardless of the initial ATA 
risk classification: TSH should be maintained between 
0.1 and 0.5 mU/L, in the absence of specific contrain-
dications.
(c) Patients with an excellent (clinically and biochemically 
free of disease) response to treatment, regardless of the 
initial ATA risk classification: TSH may be kept within 
the low–normal reference range (0.5 and 2 mU/L).
(d) Patients who have not undergone remnant ablation or 
adjuvant therapy with a normal neck US, and low or 
undetectable serum Tg, and Tg or TgAb that are not ris-
ing: TSH can be allowed to rise to the reference range 
(0.5 and 2 mU/L) (Fig. 1).
Narrative of the recommendation
Retrospective and prospective studies have demonstrated 
that TSH suppression to below 0.1 mU/L may improve 
outcomes in high-risk thyroid cancer patients, though no 
such evidence of benefit has been documented in low-risk 
patients. Higher degrees of suppression to < 0.03 mU/L may 
offer no additional benefit. Almost all the available data on 
the use of thyroid hormone suppression therapy refer to 
patients submitted to total thyroidectomy, whereas there is 
little or none available data to guide TSH targets in low-risk 
patients who have undergone lobectomy.
Adverse effects of TSH suppression may include the 
known consequences of subclinical thyrotoxicosis, includ-
ing exacerbation of angina in patients with ischemic heart 
disease, increased risk for atrial fibrillation in older patients, 
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and increased risk of osteoporosis in postmenopausal 
women. Thus, a balance is needed between the potential 
benefit of TSH suppression on tumor recurrence or progres-
sion and the risks of subclinical thyrotoxicosis, especially 
in patients at high risk of adverse effects on heart and bone. 
When a TSH suppressive treatment has an absolute indica-
tion, adjunctive therapy with calcium supplements, vitamin 
D, and other bone enhancing agents (bisphosphonates, deno-
sumab, etc.) should be considered in peri- and postmenopau-
sal women at risk for bone loss.
Finally, the appropriate degree of TSH suppression by 
thyroid hormone therapy during follow-up is still unknown, 
especially in high-risk patients who become free of disease 
after initial treatment. This is because discordant data are 
available, some studies indicating that the degree of TSH 
suppression is an independent predictor of recurrence, and 
others showing that the degree of TSH suppression does not 
correlated with outcome.
Item 24: Legal issue in the management 
of thyroid cancer
Background
The frequency of medical-legal issues in the management 
of thyroid cancer is rising everywhere in the world and also 
in Italy, particularly in the setting of surgical treatment. 
Knowledge of the character and frequency of such problem 
following surgery of the thyroid gland is scant; however, it is 
apparent that post-operative recurrent laryngeal nerve palsy 
and hypoparathyroidism are the principal causes of surgical 
malpractice claims. There are no specific data regarding the 
extent of the medical-legal controversies regarding thyroid 
cancer management in Italy.
Recommendation statement
(a) National clinical practice guidelines may not necessar-
ily constitute a legal standard of care in jurisdiction.
(b) In Italy, a law is currently under discussion regarding 
regulation concerning professional responsibility of 
health care personnel. This law provides a number of 
changes from the law currently in force, especially with 
regard to the criminalization of medical procedures. It 
establishes a set of rules that would regulate conflicts 
in the forensic field.
(c) A good informed consent is the basis for lowering med-
ical conflict. It is important to establish a relationship 
of alliance and empathy between doctor and patient.
Narrative of the recommendation
This document is intended to inform clinical decision mak-
ing. A major goal of this consensus statement is to minimize 
potential harm from overtreatment in a majority of patients 
After initial treatment
TSH           ≤0.1                     0.1-0.5                              0.5-2                           0.1-0.5                       0.5-2
ATA 
high risk
ATA 
intermediate risk
Low risk
131I yes or not
Undetectable Tg 
and neg Tg Ab
Low risk
131I yes 
Low Tg 
and neg TgAb
Low risk
lobectomy
During follow-up
TSH             ≤0.1                                   0.1-0.5                                  0.5-2                              0.5-2
Structural 
incomplete response
Biochemical
incomplete or 
indeterminate response
Excellent response No remnant ablation
Excellent response
Comorbidities 
and/or age>65 yrs     TSH         0.1-0.5                    0.5-2                                0.5-2 0.5-2                        0.5-2
Comorbidities 
and/or age>65 yrs     TSH           0.1-0.5                                 0.5-2                                     0.5-2                               0.5-2
Fig. 1  Goal TSH levels after initial treatment and during follow-up according to the risk stratification
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at low risk for disease-specific mortality and morbidity, 
while appropriately treating and monitoring those patients 
at higher risk. This document should not be interpreted as 
a replacement for clinical judgement and should be used to 
complement informed, shared patient–health care provider 
deliberation on complex issues.
The safety of treatment is an integral part of the right to 
health care and is pursued in the interest of the individual 
and the community.
(Criminal liability of the operator in the health care pro-
fession). The operator of the health care profession that, 
in carrying out his or her activities, due to inexperience, 
causes death or personal injury of the patient is liable for 
offenses referred to only in cases of gross negligence. The 
effects of the provisions of the first paragraph exclude gross 
negligence when, subject to the relevant specificities of the 
case, they comply with good clinical care practices and rec-
ommendations provided by the guidelines, as defined and 
published in accordance with the law.
Informed consent: patients should be adequately informed 
by the operator of the indications for an individual treatment 
or possible alternative treatments, the expected advantages 
from the therapy, its general and specific complications 
and possible rehabilitation therapy, as well as the clinical 
consequences of potential permanent injuries, particularly 
after surgery. The information provided should be clearly 
explained, complete and prompt. After providing the most 
complete information, the physician will seek the patient’s 
consent to perform therapy, especially taking into full con-
sideration any expression of dissent, even on individual 
aspects of the procedure or its potential consequences [73, 
74]. Transmission of information and the informed consent 
should preliminarily take place at the initial outpatient visit 
and be renewed at admission, especially if enough time has 
passed such that the initial conditions may have changed. In 
fact, the patient must be given the opportunity to discuss in 
depth with his/her physician (or other trusted persons) the 
information received and, if desired, get information on the 
health facility where he or she will be treated and/or on the 
team that will perform therapy. Given the peculiarity of the 
therapeutic intervention in case of surgery (partial or total 
removal of thyroid glands and neck nodes, central o lateral) 
and its potential consequences on the physical integrity of 
the subject, it is necessary that written documentation of 
the informed and voluntary consent be retained, and that 
the informed consent process be documented in a specific 
chart note.
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Appendix 1: Reporting form for thyroid 
tumors
Gross description (macroscopic)
Thyroid
Weight (size)
Multinodularity/uninodularity
Macroscopic appearance of the nodule:
• diameter
• homogeneous/heterogeneous
• tumor color
• expansive margins/infiltrative margins
• presence/absence of a capsule
• solid/colloid
• cystic-hemorrhagic regression
• calcifications (pattern and location).
Site
• right lobe
• left lobe
• isthmus
• pyramidal lobe
Distance from thyroid capsule/surgical margins
Lymph nodes
Site
Size of the specimen
Gross features of the largest nodes.
Microscopic examination
Thyroid nodule
Capsule (present/absent)
Structure (colloid/sclerotic/solid)
Histotype
NIFT-P
Papillary
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Classical variant
Follicular variant
Follicular
Minimally invasive
Widely invasive
Oncocytic
Poorly differentiated (insular)
Anaplastic
Medullary
Thyroid lymphoma
Secondary tumors
Aggressive variants of PTC:
• hobnail (report the presence)
• tall cells (more than 10%)
• solid (percentage value)
• columnar cell (more than 10%)
• diffuse sclerosing (report the presence)
Capsular invasion (tumor capsule/thyroid capsule)
Vascular invasion (no. of vessels: 4 or more) [19]
Minimal muscular invasion (strap muscles)
Extrathyroidal invasion (subcutaneous soft tissues, lar-
ynx, trachea, esophagus, recurrent laryngeal nerve, pre-
vertebral fascia, neck muscles, large vessels) [20]
Immunohistochemistry and molecular analysis (if per-
formed).
Lymph nodes
Total number
Number of metastatic nodes
Size of the largest metastatic area within the node, micro- 
(< 2 mm) or macrometastases Presence of extranodal 
invasion [75–77].
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